View in EDS HTML Full Text PDF Full Text

A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.

Saved in:
Bibliographic Details
Title: A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Authors: Rajdev L; Zucker School of Medicine at Hofstra, Hempstead, NY, USA. lrajdev2@gmail.com., Lee JW; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA., Libutti SK; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Benson AB; Northwestern University, Evanston, IL, USA., Fisher GA Jr; Stanford University, Stanford, CA, USA., Kunz PL; Yale School of Medicine, New Haven, CT, USA., Hendifar AE; Cedars-Sinai Medical Center, Los Angeles, CA, USA., Catalano P; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA., O'Dwyer PJ; University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA, USA.
Source: Investigational new drugs [Invest New Drugs] 2022 Dec; Vol. 40 (6), pp. 1306-1314. Date of Electronic Publication: 2022 Oct 20.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36264382
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Rajdev+L%22">Rajdev L</searchLink>; Zucker School of Medicine at Hofstra, Hempstead, NY, USA. lrajdev2@gmail.com.<br /><searchLink fieldCode="AU" term="%22Lee+JW%22">Lee JW</searchLink>; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Libutti+SK%22">Libutti SK</searchLink>; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Benson+AB%22">Benson AB</searchLink>; Northwestern University, Evanston, IL, USA.<br /><searchLink fieldCode="AU" term="%22Fisher+GA+Jr%22">Fisher GA Jr</searchLink>; Stanford University, Stanford, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kunz+PL%22">Kunz PL</searchLink>; Yale School of Medicine, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Hendifar+AE%22">Hendifar AE</searchLink>; Cedars-Sinai Medical Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Catalano+P%22">Catalano P</searchLink>; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22O'Dwyer+PJ%22">O'Dwyer PJ</searchLink>; University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2022 Dec; Vol. 40 (6), pp. 1306-1314. <i>Date of Electronic Publication: </i>2022 Oct 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36264382
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10637-022-01311-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1306
    Titles:
      – TitleFull: A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rajdev L
      – PersonEntity:
          Name:
            NameFull: Lee JW
      – PersonEntity:
          Name:
            NameFull: Libutti SK
      – PersonEntity:
          Name:
            NameFull: Benson AB
      – PersonEntity:
          Name:
            NameFull: Fisher GA Jr
      – PersonEntity:
          Name:
            NameFull: Kunz PL
      – PersonEntity:
          Name:
            NameFull: Hendifar AE
      – PersonEntity:
          Name:
            NameFull: Catalano P
      – PersonEntity:
          Name:
            NameFull: O'Dwyer PJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2022 Dec
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1573-0646
          Numbering:
            – Type: volume
              Value: 40
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Investigational new drugs
              Type: main
ResultId 1